JPRN-jRCTs061180101招募中1 期
Phase I/II clinical trial of HB vaccine containing HBsAg and HBcAg for prophylaxis - HepBVac-J2
Hiasa Yoichi0 个研究点目标入组 100 人开始时间: 2019年3月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 65age old（—）
- 性别
- All
入选标准
- •Healthy individuals agreed to participate in this trial after obtaining writen informed consent
- •a) HB vaccine naive: No pasthistory of HB vaccination
- •b) HB vaccine responder: Anti-HBs > 10mIU/mL after HB vaccination
- •c) HB vaccine non-responder: Anti-HBs < 10mIU/mL after HB vaccination
- •(1) Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2
- •(2) No evidence of organ dysfunction
- •Liver: Child-Pugh Score < 9
- •Kidney: eGFR > 30ml/min
- •Heart: No abnormality in ECG
- •Lung: SpO2 >92%
排除标准
- •(1) Allergic history against past vaccination
- •(2) Pregnant, unwilling to practice contraception during the study or lactating female
- •(3) Severe complication (malignant hypertension, severe congestive heart failure, severe liver failure, poorly controlled diabetes mellitus, severe pulmonary fibrosis, active interstitial pneumonia)
- •(4) Bearing malignant carcinoma including HCC
- •(5) Severe mental disability
- •(6) Positive for HCV-RNA
- •(7) Taking immunosuppressive drugs, steroid and interferons
- •(8) Inappropriate to participate in this trial
研究者
相似试验
已完成
不适用
A randomised trial of hepatitis B booster vaccination at the age of 13 to 15 years following infant vaccination to assess efficacy against hepatitis B infection and acute hepatitisHepatitis BISRCTN71271385Medical Research Council (MRC) (UK)500
已完成
1 期
PhaseI/II clinical study of peptide vaccine against advanced or recurrent gastric cancerAdvanced or recurrent gastric cancer refractory to standard therapeutic modalityJPRN-UMIN000004389Department of Gastroenterological Surgery,Graduate School of Medicine,Osaka University30
进行中（未招募）
1 期
Phase I/II trial for vaccine therapy with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion in patients with metastatic malignant melanomaEUCTR2008-006253-41-NOThe Norwegian Radium Hospital, Oslo University Hospital25
已完成
2 期
Phase II clinical trial of peptide vaccination with HLA-A2402-restricted KIF20A and VEGFR1 epitope peptides with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancerpancreatic cancerJPRN-UMIN000004641Department of Gastroenterology Juntendo University School of Medicine40
进行中（未招募）
不适用
An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study) - NDProstate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated levels of testosterone or after first-line anti hormonal therapyMedDRA version: 12.1Level: LLTClassification code 10001200Term: Adenocarcinoma of the prostate stage IEUCTR2009-017798-39-ITISTITUTO NAZIONALE PER LA CURA TUMORI